A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

IT’S a disease that only affects old men. Wrong. You won’t die of it, you die with it. Wrong again! Prostate cancer is the most common cancer in England, overtaking breast cancer for the first ...

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

The number of cancer diagnoses in the Netherlands increased again last year, rising by 3,000 to around 130,000 people finding ...

Dante’s oncologist, Dr. Bernie Eigl, deputy head, department of clinical research at BC Cancer, referred him to a BC Cancer ...

Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation ...

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...